Research programme: viral budding inhibitors - Biotron

Drug Profile

Research programme: viral budding inhibitors - Biotron

Alternative Names: BIT 009; Next-generation viroporin inhibitors - Biotron

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotron
  • Developer Biotron; ImQuest BioSciences; National Institutes of Health (USA)
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus p7 protein inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; Human immunodeficiency virus 1 vpu protein inhibitors; SARS coronavirus E protein-inhibitors; Viral protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Coronavirus infections; Dengue; Hepatitis C; HIV infections

Highest Development Phases

  • Preclinical Hepatitis C; HIV infections
  • Research Dengue; Zika virus infection
  • No development reported Coronavirus infections

Most Recent Events

  • 16 Feb 2016 Early research in Zika virus infection in Australia (unspecified route)
  • 03 Dec 2014 Early research is ongoing for Dengue
  • 05 Jun 2013 Preclinical development is ongoing for HCV and HIV infections in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top